Mene Pangalos is given a knighthood for services to UK science, alongside NHS England’s Simon Stevens and Quintiles founder Dennis Gillings.
AstraZeneca’s R&D chief Mene Pangalos has been awarded a knighthood in the New Year 2020 Honours List in recognition of his services to UK science.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.
